Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Weighted Average)
Others
Ratios

KalVista Pharmaceuticals (KALV) EBIT: 2014-2025

Historic EBIT for KalVista Pharmaceuticals (KALV) over the last 7 years, with Apr 2025 value amounting to -$45.8 million.

  • KalVista Pharmaceuticals' EBIT rose 5.46% to -$45.8 million in Q2 2025 from the same period last year, while for Apr 2025 it was -$171.6 million, marking a year-over-year decrease of 66.17%. This contributed to the annual value of -$188.0 million for FY2025, which is 33.86% down from last year.
  • Latest data reveals that KalVista Pharmaceuticals reported EBIT of -$45.8 million as of Q2 2025, which was down 3.61% from -$44.2 million recorded in Q3 2024.
  • KalVista Pharmaceuticals' EBIT's 5-year high stood at -$33.2 million during Q1 2024, with a 5-year trough of -$48.5 million in Q2 2024.
  • Its 2-year average for EBIT is -$42.9 million, with a median of -$45.0 million in 2024.
  • Data for KalVista Pharmaceuticals' EBIT shows a peak YoY grew of 5.46% (in 2025) over the last 5 years.
  • KalVista Pharmaceuticals' EBIT (Quarterly) stood at -$44.2 million in 2024, then rose by 5.46% to -$45.8 million in 2025.
  • Its EBIT was -$45.8 million in Q2 2025, compared to -$44.2 million in Q3 2024 and -$48.5 million in Q2 2024.